Hernández Fernández C.P., Borrego L., Mercader García P., Giménez Arnau A.M., Sánchez Pérez J., Silvestre Salvador J.F., González Pérez R., Sanz Sánchez T., Sánchez Gilo A., Melé Ninot G., Zaragoza Ninet V., Miquel Miquel F.J., Carrascosa Carrillo J.M., Córdoba Guijarro S., Gatica Ortega M.E., Ruiz González I., Serra Baldrich E., Tous Romero F., Rodríguez Serna M., Pastor Nieto M.A., Pérez Feal P., Hervella Garcés M., de Vega Martínez M., García Doval I.. Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situation. CONTACT DERMATITIS. 2023; 88(3)DOI:10.1111/cod.14251. PMID:36403138. IF:4.800(Q1/2D).

Yélamos O., Andersen D., Pont M., Iglesias P., Potrony M., Domínguez M., Herrero A., Alejo B., Mateu J., Røpke M., Danneskiold-Samsøe N.B., Malvehy J., Guy R.H., Brix S., Puig S.. Development and validation of a minimally invasive and image-guided tape stripping method to sample atopic skin in children. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2023; 48(2)DOI:10.1093/ced/llac040. PMID:36730521. IF:3.700(Q1/2D).

Puig L.. Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(2)DOI:10.1093/bjd/ljac081. PMID:36763894. IF:11.000(Q1/1D).

Egeberg A., Merola J.F., Schäkel K., Puig L., Mahar P.D., Wang I.Y., Pavo I., Schuster C., Griffiths C.E.M.. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. Frontiers in Medicine. 2023; 9DOI:10.3389/fmed.2022.1092688. PMID:36777159. IF:3.100(Q1/2D).